AN-019

CAS No. 879507-25-2

AN-019( —— )

Catalog No. M34157 CAS No. 879507-25-2

AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AN-019
  • Note
    Research use only, not for human use.
  • Brief Description
    AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
  • Description
    AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Bcr-Abl
  • Recptor
    Bcr-Abl
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    879507-25-2
  • Formula Weight
    517.43
  • Molecular Formula
    C25H17F6N5O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=CC=C(C(=C1)NC=2N=CC=C(N2)C3=CN=CC=C3)C)C=4C=C(C=C(C4)C(F)(F)F)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Dasatinib hydrochlor...

    A potent, orally bioavailable, dual Src/Abl kinase inhibitor with IC50 of 0.5, 0.4, 0.5 and <1 nM for Src, Lck, Yes and Bcr-Abl, respectively.

  • Nilotinib monohydroc...

    A potent, selective, orally available inhibitor of both native and mutant Bcr-Abl with IC50 of 20-80 nM.

  • ABL-IN-29

    ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively.